Early plasma interferon-β levels as a predictive marker of COVID-19 severe clinical events in adult patients.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
01 2023
Historique:
revised: 09 11 2022
received: 21 09 2022
accepted: 25 11 2022
pubmed: 2 12 2022
medline: 11 1 2023
entrez: 1 12 2022
Statut: ppublish

Résumé

We assessed relationships between early peripheral blood type I interferons (IFN) levels, clinical new early warning scores (NEWS), and clinical outcomes in hospitalized coronavirus disease-19 (COVID-19) adult patients. Early IFN-β levels were lower among patients who further required intensive care unit (ICU) admission than those measured in patients who did not require an ICU admission during severe acute respiratory syndrome coronavirus type 2 infection. IFN-β levels were inversely correlated with NEWS only in the subgroup of patients who further required ICU admission. To assess whether peripheral blood IFN-β levels could be a potential relevant biomarker to predict further need for ICU admission, we performed receiver operating characteristic (ROC) curve analyses that showed for all study patients an area under ROC curve of 0.77 growing to 0.86 (p = 0.003) when the analysis was restricted to a subset of patients with NEWS ≥5 at the time of hospital admission. Overall, our findings indicated that early peripheral blood IFN-β levels might be a relevant predictive marker of further need for an ICU admission in hospitalized COVID-19 adult patients, specifically when clinical score (NEWS) was graded as upper than 5 at the time of hospital admission.

Identifiants

pubmed: 36451263
doi: 10.1002/jmv.28361
pmc: PMC9877952
doi:

Substances chimiques

Interferon-beta 77238-31-4
Biomarkers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e28361

Informations de copyright

© 2022 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Références

J Immunol. 2007 Feb 1;178(3):1457-67
pubmed: 17237394
Science. 2020 Oct 23;370(6515):
pubmed: 32972996
J Med Virol. 2021 Apr;93(4):2476-2486
pubmed: 33404091
Science. 2020 Aug 7;369(6504):718-724
pubmed: 32661059
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Science. 2020 Oct 23;370(6515):
pubmed: 32972995
Future Virol. 2022 Mar;:
pubmed: 35462619
Resuscitation. 2020 Nov;156:84-91
pubmed: 32918985
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Nat Rev Immunol. 2015 Feb;15(2):87-103
pubmed: 25614319
J Med Virol. 2020 Oct;92(10):2105-2113
pubmed: 32383269
J Med Virol. 2023 Jan;95(1):e28361
pubmed: 36451263
Nat Commun. 2020 Jul 30;11(1):3810
pubmed: 32733001
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
J Allergy Clin Immunol. 2021 Jun;147(6):2098-2107
pubmed: 33894209

Auteurs

Fatma Berri (F)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.

Yohan N'Guyen (Y)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.
Internal Medicine, Infectious Diseases and Clinical Immunology, Robert Debré University Hospital, Reims, France.

Domitille Callon (D)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.
Pathology Department, CHU Reims, Hôpital Robert Debré, Reims, France.

Anne-Laure Lebreil (AL)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.

Marie Glenet (M)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.

Laetitia Heng (L)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.

Bach-Nga Pham (BN)

Immunology Department, CHU Reims, Hôpital Robert Debré, Reims, France.

Firouze Bani-Sadr (F)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.
Internal Medicine, Infectious Diseases and Clinical Immunology, Robert Debré University Hospital, Reims, France.

Laurent Andreoletti (L)

EA4684 Cardiovir Research Laboratory, University of Reims Champagne-Ardenne, Reims, France.
Virology Department, CHU Reims, Hôpital Robert Debré, Reims, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH